Journals / Retina-Vitreus / 2011 / Cilt: 19 - Sayı: 2

Yaşa bağlı maküla dejenerasyonuna bağlı koroidal neovaskülarizasyon tedavisinde tek başına bevacizumab veya fotodinamik tedavi ile kombinasyon: 12 ay sonuçları

Treatment of choroidal neovascularization secondary to age-related macular degeneration with intravitreal bevacizumab monotherapy or combination with photodynamic therapy: 12 month results

Pages
97–102
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

An activity scoring-guided strategy may help to determine the need for retreatments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To determine the anatomical and visual responses to intravitreal bevacizumab injection (IVB) monotherapy and the combination of IVB with photodynamic therapy (PDT) in neovascular age-related macular degeneration (AMD).
📊
Key Findings & Data:The eyes were divided into 2 groups: the 1st group received only IVB and the 2nd group received IVB+PDT.
💡
Conclusion & Impact:An activity scoring-guided strategy may help to determine the need for retreatments.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To determine the anatomical and visual responses to intravitreal bevacizumab injection (IVB) monotherapy and the combination of IVB with photodynamic therapy (PDT) in neovascular age-related macular degeneration (AMD). Materials and Methods: This was a prospective study that involved treatment of naive eyes with neovascular AMD. The eyes were divided into 2 groups: the 1st group received only IVB and the 2nd group received IVB+PDT. An activity score (AS) was given to each lesion during all visits. Student&#8217;s t test and chi-square test were used for the comparison of parameters. Results: A total of 53 eyes were involved in the study. Mean follow-up time was 12.3 months. There was no significant difference with respect to lesion type, visual acuity, or central foveal thickness between the groups before treatment. After treatment AS decreased significantly in the two groups (p<0.05). Visual acuity was the same or increased in 92.5% of the eyes in group 1 and in 88.5% of the eyes in group 2 (p>0.05). The mean number of IVB/eye was 2.7 in group 1 and 2.6 in group 2 (p>0.05). Conclusion: IVB+PDT combination therapy seems not to be superior to IVB monotherapy with respect to visual acuity or retreatment needs in neovascular AMD. An activity scoring-guided strategy may help to determine the need for retreatments.

Özet

Amaç: Neovasküler yaşa bağlı maküla dejenerasyonunda (YBMD), tek başına intravitreal bevacizumab enjeksiyonu (İVB) ile fotodinamik tedavi (FDT) ve İVB kombinasyon tedavisinin anatomik ve görsel sonuçlarının değerlendirilmesi. Gereç ve Yöntem: Bu geriye dönük çalışmaya daha önce tedavi almamış neovasküler YBMD’li gözler dahil edildi. Çalışma tek başına İVB tedavisi alan 1. grup ve İVB+FDT tedavisi alan 2. grup olmak üzere toplam 2 gruptan oluşturuldu. Tedavi öncesi ve sonrası tüm kontrollerde her lezyona bir aktivite skoru (AS) verildi. Parametrelerin karşılaştırılmasında Student’s t testi ve Ki-kare testi kullanıldı. Bulgular: Çalışmaya toplam 53 göz dahil edildi. Ortalama takip süresi 12.3 ay idi. Tedavi öncesinde gruplar arasında lezyon tipi, görme keskinliği ve santral foveal kalınlık açısında bir fark izlenmedi. Tedavi sonrasında AS her iki grupta da anlamlı olarak azaldı (p 0.05). Ortalama İVB/göz sayısı 1. grupta 2.7, 2. grupta ise 2.6 olarak hesaplandı (p>0.05). Sonuç: İVB+FDT kombinasyon tedavisi tek başına İVB tedavisine göre, görme keskinliği ve tekrar tedavi ihtiyacı açısından üstün görünmemektedir. Tekrar tedavi ihtiyacının belirlenmesinde aktivite skorlama sisteminin kullanılması yardımcı olabilir.

🔖

Cite This Article

GEDİZ, B. Ş., ÖZDEK, Ş., ÖZMEN, M. C., GÜRELİK, G., HASANREİSOĞLU, B. (2011). Yaşa bağlı maküla dejenerasyonuna bağlı koroidal neovaskülarizasyon tedavisinde tek başına bevacizumab veya fotodinamik tedavi ile kombinasyon: 12 ay sonuçları. Retina-Vitreus, Cilt: 19 - Sayı: 2, 97–102. https://ajindex.com/articles/308078

References (13)

  1. NG EW, Adamis AP.: Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368
  2. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al.: VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351:2805-2816
  3. Ruckman J, Green LS, Beeson J, et al.: 2’-Fluoropyrimidine RNAbased aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGFinduced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998;273:20556-20567
  4. Rosenfeld PJ, Brown DM, Heier JS, et al.: Marina Study Group. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1419-1431
  5. Brown DM, Kaiser PK, Michels M, et al.: Anchor Study Group. Ranibizumab versus Verteporfin for neovascular agerelated macular degeneration. N Eng J Med. 2006;355:1432-1444
  6. Regillo CD, Brown DM, Abraham P, et al.: Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248
  7. Antoszyk AN, Tuomi L, Chung CY, et al.: FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145:862-874
  8. Rosenfeld PJ, Moshfeghi AA, Puliafito CA.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335
  9. Avery RL, Pieramici DJ, Rabena MD, et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372
  10. Rich RM, Rosenfeld PJ, Puliafito CA, et al.: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina. 2006;26:495-511
  11. Spaide RF, Laud K, Fine HF, et al.: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390
  12. Yoganathan P, Deramo VA, Lai JC, et al.: Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina. 2006;26:994-998
  13. Lazic R, Gabric N.: Intravitreally administered bevacizumab (Avastin)